Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | PAK4 | O96013 | 3/20 | 0.41 |
| ▸ | CSF1R | P07333 | 3/20 | 0.41 |
| ▸ | RET | P07949 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 3/20 | 0.41 |
| ▸ | PIM1 | P11309 | 3/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | PRKACA | P17612 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | LTK | P29376 | 3/20 | 0.41 |
| ▸ | GRK5 | P34947 | 3/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.41 |
| ▸ | CLK2 | P49760 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769366 | 0.85 | TGFBR1 (0.38) | DYRK1ATGFBR1 | |
| SCHEMBL5474088 | 0.76 | CLK4 (0.44) | JAK3KDRJAK2MAP4K4CSF1R | |
| SCHEMBL2522143 | 0.76 | ADORA2B (0.36) | TGFBR1 | |
| SCHEMBL2601265 | 0.73 | JAK2 (0.63) | JAK3KDRJAK2DAPK3PRKD3 | |
| SCHEMBL28212089 | 0.70 | JAK2 (0.59) | JAK3KDRJAK2DAPK3PRKD3 | |
| SCHEMBL3639239 | 0.69 | JAK2 (0.54) | JAK3KDRJAK2DAPK3PRKD3 | |
| SCHEMBL28962329 | 0.65 | KDR (0.55) | JAK3KDRJAK2DAPK3PRKD3 | |
| Ammonia Solution, Strong SCHEMBL3777371 | 0.64 | TGFBR1 (0.35) | KDRPIM1TGFBR1 | |
| SCHEMBL24302730 | 0.64 | JAK2 (0.53) | JAK3KDRJAK2DAPK3PRKD3 | |
| SCHEMBL13885299 | 0.64 | JAK2 (0.63) | JAK3KDRJAK2DAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8557830-B2 | RAF kinase modulators and methods of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324047-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | JAK3 348/4885KDR 700/4885JAK2 268/4885 |
| US-20140005198-A1 | RAF KINASE MODULATORS AND METHODS OF USE | BRAF, RAF1, ARAF | JAK3 355/4885KDR 873/4885JAK2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.